AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01508494
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 mg galantamine daily P/O
Trial: NCT02356146
Drug: Tacrolimus C12
RxNorm normalized name: C12:0
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04561245
Drug: ALT-801
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (SC)
Trial: NCT04315480
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single intravenous administration 8mg/Kg
Trial: NCT03792451
Drug: Pegvaliase
RxNorm normalized name: PEGVALIASE
DrugBank: Pegvaliase (DB12839)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
Trial: NCT03895112
Drug: AVID200
RxNorm normalized name: Tgf-beta 1/3 inhibitor avid200
DrugBank: AVID-200 (DB18454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose cohorts of 21-day cycles
Trial: NCT02651792
Drug: ketamine- propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
Trial: NCT02651792
Drug: pethidine- propofol
RxNorm normalized name: pethidine
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
Trial: NCT01103778
Drug: Bortezomib (Velcade®)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
Trial: NCT03067129
Drug: Glecaprevir/Pibrentasvir Adult Formulation
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Co-formulated film-coated tablet (100 mg/40 mg)
Trial: NCT03067129
Drug: Glecaprevir + Pibrentasvir Pediatric Formulation
RxNorm normalized name: glecaprevir / pibrentasvir
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
Trial: NCT00397176
Drug: desvenlafaxine succinate sustained release (DVS SR)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00049218
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00049218
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00430963
Drug: IncobotulinumtoxinA (Xeomin) (20 Units)
RxNorm normalized name: incobotulinumtoxinA 100 UNT [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT00783172
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
Trial: NCT01978509
Drug: Low volume prep (Prepopik)
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Trial: NCT01978509
Drug: High volume prep (Golytely)
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Trial: NCT02293356
Drug: Nimotuzumab Injection
RxNorm normalized name: inotuzumab ozogamicin Injection
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
Trial: NCT00091026
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00091026
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01896388
Drug: Ifenprodil Tartrate
RxNorm normalized name: ifenprodil tartrate
DrugBank: Ifenprodil (DB08954)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03002103
Drug: EndoTAG-1
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03002103
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03002103
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00217516
Drug: selenium
RxNorm normalized name: Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02294006
Drug: Everolimus plus Octreotide LAR plus Metformin
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Everolimus plus Octreotide LAR plus Metformin
Trial: NCT04782037
Drug: L-Methylfolate Calcium
RxNorm normalized name: L-Methylfolate Calcium
DrugBank: Levomefolic acid (DB11256)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
Trial: NCT00378755
Drug: velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01588353
Drug: Collagenase Clostridium Histolyticum
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
Trial: NCT01700985
Drug: 122-0551
RxNorm normalized name: MSX-122
DrugBank: MSX-122 (DB12715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied twice daily for two weeks
Trial: NCT01158729
Drug: Antithrombin (Recombinant)
RxNorm normalized name: Antithrombin (recombinant)
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
Trial: NCT00033033
Drug: Reserpine
RxNorm normalized name: Reserpine
DrugBank: Reserpine (DB00206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00141700
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02790671
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg itraconazole
Trial: NCT01788982
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib should be administered orally at a dose of 200 mg twice daily.
Trial: NCT00461578
Drug: Chlorproguanil-dapsone + artesunate
RxNorm normalized name: Artesunate
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02180217
Drug: osilodrostat
RxNorm normalized name: osilodrostat
DrugBank: Osilodrostat (DB11837)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
Trial: NCT04141553
Drug: Diltiazem Injection
RxNorm normalized name: diltiazem Injection
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization to one of to active comparator groups
Trial: NCT02595840
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02595840
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02411526
Drug: ZX003 (Risperidone-SABER®)
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZX003 administered as a SC injection
Trial: NCT02411526
Drug: Risperdal Consta
RxNorm normalized name: RisperDAL Consta
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperdal Consta administered as a IM injection
Trial: NCT02411526
Drug: Oral Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
Trial: NCT02807363
Drug: Leuprolide Oral Tablet 4-mg QD
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg Leuprolide oral tablet once daily for 28 consecutive days.
Trial: NCT02807363
Drug: Leuprolide Oral Tablet 4-mg BID
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
Trial: NCT02807363
Drug: Leuprolide Depot
RxNorm normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg intramuscular depot injection
Trial: NCT02807363
Drug: Leuprolide Oral Tablet 10-mg BID
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
Trial: NCT00744016
Drug: Granulated mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
Trial: NCT01195363
Drug: quetiapine SR
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine SR, dose range 200-600mg, each night QHS for 6mos
Trial: NCT01195363
Drug: quetiapine sr placebo
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
Trial: NCT02188719
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
Trial: NCT02188719
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF
Trial: NCT02188719
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
Trial: NCT02188719
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
Trial: NCT02188719
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
Trial: NCT02188719
Drug: Anti-Infective Prophylaxis
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
Trial: NCT01214941
Drug: Ticlopidine
RxNorm normalized name: Ticlopidine
DrugBank: Ticlopidine (DB00208)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
Trial: NCT01214941
Drug: Ticlopidine and itraconazole
DrugBank: Ticlopidine (DB00208)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
Trial: NCT02726113
Drug: cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
Trial: NCT02058485
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
Trial: NCT02058485
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
Trial: NCT01578785
Drug: Glatiramer Acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
Trial: NCT00966693
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00966693
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00966693
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00255294
Drug: Cellulose sulfate vaginal gel
RxNorm normalized name: cellulose sulfate
DrugBank: Sodium cellulose phosphate (DB06776)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02697630
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
Trial: NCT02697630
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
Trial: NCT01273389
Drug: CNTO 136
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
Trial: NCT04326023
Drug: PARP Inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olaparib, rucaparib, niraparib, talazoparib, veliparib
Trial: NCT00377429
Drug: catumaxomab
RxNorm normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
Trial: NCT02013089
Drug: Erlotinib or Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
Trial: NCT02013089
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
Trial: NCT02013089
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
Trial: NCT05396898
Drug: LCP-tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylaxis of transplant rejection in liver and kidney allograft recipients
Trial: NCT02013089
Drug: Sorafenib or Sunitinib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
Trial: NCT02013089
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg orally once daily for patients with RET gene fusion.
Trial: NCT01718626
Drug: S1+Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
Trial: NCT01718626
Drug: S1+Docetaxel followed by S1
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
Trial: NCT01928563
Drug: Dapoxetine
RxNorm normalized name: dapoxetine
DrugBank: Dapoxetine (DB04884)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928563
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928563
Drug: Udenafil+Dapoxetine
RxNorm normalized name: udenafil
DrugBank: Dapoxetine (DB04884)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01033487
Drug: active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled formulation, single dose
Trial: NCT01033487
Drug: Low Dose PF-03635659
RxNorm normalized name: ethinyl estradiol
DrugBank: PF-03635659 (DB12408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled formulation, single dose, low dose
Trial: NCT01033487
Drug: Mid Dose PF-03635659
RxNorm normalized name: PF-03635659
DrugBank: PF-03635659 (DB12408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled formulation, single dose, mid dose
Trial: NCT01033487
Drug: High Dose PF-03635659
RxNorm normalized name: PF-03635659
DrugBank: PF-03635659 (DB12408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled formulation, single dose, high dose
Trial: NCT04218799
Drug: Intranasal Mupirocin and Topical Chlorhexidine
RxNorm normalized name: mupirocin Topical Cream
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
Trial: NCT02849626
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: E2007